Skip to main content

Table 1 Relationship between the expression of miR-148a and clinicopathological features in hepatocellular carcinoma (HCC) x ¯ ± s

From: Decreased expression and clinical significance of miR-148a in hepatocellular carcinoma tissues

Clinicopathological features

n

MiR-148a relevant expression

2 -â–³ cq

t

P

Tissue

HCC

89

0.87 ± 0.50

−7.762∆

< 0.001

Adjacent noncancerous liver

89

1.44 ± 0.61

Age

≥ 50

43

0.83 ± 0.49

−0.727

0.469

< 50

46

0.91 ± 0.51

Gender

Male

72

0.88 ± 0.50

0.392

0.696

Female

17

0.83 ± 0.53

Differentiation

Well

6

0.88 ± 0.40

F = 0.531a

0.590

Moderately

57

0.91 ± 0.52

Poorly

26

0.79 ± 0.48

Clinical TNM stage

I to II

19

1.17 ± 0.58

3.106

0.003

III to IV

70

0.79 ± 0.45

Metastasis

Yes

46

0.74 ± 0.51

−2.537

0.013

No

43

1.00 ± 0.46

With cirrhosis

Yes

43

0.86 ± 0.52

−0.143

0.886

No

46

0.88 ± 0.48

AFP (μg/L)

≥ 400

35

0.90 ± 0.51

−0.015

0.988

< 400

38

0.90 ± 0.49

Portal vein tumor embolus

Yes

29

0.76 ± 0.53

−1.400

0.165

No

60

0.92 ± 0.48

Tumor capsular infiltration

No capsular or capsular infiltration

48

0.76 ± 0.49

−2.308

0.023

No capsular infiltration

41

1.00 ± 0.49

Tumor nodes

Multiple

40

0.75 ± 0.47

−2.015

0.047

Single

49

0.96 ± 0.51

Tumor diameter (cm)

≥ 5

73

0.91 ± 0.51

1.515

0.133

< 5

15

0.70 ± 0.46

Vaso-invasion

Yes

32

0.79 ± 0.53

−1.116

0.267

 

No

56

0.92 ± 0.49

  

HBV infection

Yes

73

0.84 ± 0.51

−1.347

0.181

 

No

16

1.02 ± 0.45

  

HCV infection

Yes

29

0.94 ± 0.51

0.912

0.364

 

No

60

0.84 ± 0.50

  
  1. ∆Paired t-student test was performed.
  2. aOne-way analysis of variance (ANOVA) test was performed.